The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
Nine years after a groundbreaking deal with Pfizer, Cellectis goes to AstraZeneca for a fresh lease of life.
Assets targeting PSMA and KRAS G12V, plus another gamma-delta Car-T therapy, feature among recently disclosed first-time clinical trial entrants.
But today’s deal with Jiangsu Hengrui doesn’t mean that the group is turning away from an earlier tie-up with Nerviano.
The dust has settled on a momentous ESMO conference, which saw biotech activity amid big pharma’s practice-changing data.
The study of Novartis’s Pluvicto in pre-chemo prostate cancer is a bust on overall survival, with questions raised about trial design.
The presidential session heralds a combo of Padcev and Keytruda as the new front-line bladder cancer standard of care.